Non-Hematological Cancers Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, February 20, 2017 /EINPresswire.com/ -- Summary
In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/464286-global-non-hematological-cancers-market-to-targeted-treatments-and-versatile-biologics

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope
Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021
- What is the generic penetration?
- Which drugs will achieve blockbuster status?
Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline
- How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action are most common for pipeline drugs?
18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period
- How is their revenue share of the non-hematological cancer market set to change?
- What CAGR will these companies register in the forecast period?

Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
- Visualize the composition of the non-hematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the non-hematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the non-hematological cancer market globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-hematological cancers
- Identify commercial opportunities in the non-hematological cancer deals landscape by analyzing trends in licensing and co-development deals

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Etiology 11
2.3.2 Pathophysiology 12
2.3.3 Tumor Initiation 13
2.3.4 Enhanced Growth, Evasion of Apoptosis and Replicative Immortality 14
2.3.5 Tumor Metabolic Shift 17
2.3.6 Tumor Progression, Invasion and Metastasis 17
2.3.7 Evasion of the Immune Response 19
2.3.8 Cancer Stem Cells 20
2.4 Co-morbidities and Complications 20
2.5 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 21
2.5.1 Breast Cancer 22
2.5.2 Colorectal Cancer 22
2.5.3 Lung Cancer 23
2.5.4 Prostate Cancer 24
2.6 Treatment 25
2.6.1 Surgery and Radiation Therapy 26
2.6.2 Chemotherapy 27
2.6.3 Hormonal Therapies 29
2.6.4 Targeted Therapies 30
3 Key Marketed Products 32
3.1 Overview 32
3.2 Avastin (bevacizumab) 33
3.3 Herceptin (trastuzumab) 35
3.4 Alimta (pemetrexed) 37
3.5 Zytiga (abiraterone acetate) 38
3.6 Xtandi (enzalutamide) 39
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/464286-global-non-hematological-cancers-market-to-targeted-treatments-and-versatile-biologics


Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here